Abstracts tagged "Inflammation"

Abstract Number: 0916 • ACR Convergence 2025
UVB-Irradiated Keratinocyte Extracellular Vesicles Trigger Innate Immune Activation via Type I Interferons and STING Pathway
Ahmed Eldaboush¹, Darae Kang² and Victoria Werth³, ¹Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Potomac, MD, ³University of Pennsylvania, Wynnewood, PA
Background/Purpose: Extracellular vesicles (EVs) are cell-derived nanoparticles that mediate cell-cell communication. EVs are implicated in photosensitive autoimmune diseases like dermatomyositis (DM) and systemic lupus (SLE),…
Abstract Number: 0464 • ACR Convergence 2025
Synovial Inflammation is not Associated With Reoperation in Patients With Rheumatoid Arthritis Undergoing Total Hip or Knee Arthroplasty
Solana Cushing¹, Kelsey Gripp², Edward DiCarlo³, Deanna Jannat-Khah¹, Yoshimi Endo³, Jose Rodriguez³, Mark Figgie³, Bella Mehta⁴ and Susan Goodman³, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Reoperations following arthroplasty are a significant burden to patients and surgeons. In patients with RA who receive total hip (THA) or knee (TKA) arthroplasty,…
Abstract Number: 0207 • ACR Convergence 2025
The Feasibility and Clinical Effects of Anti-Inflammatory Diet Intervention In Patients Diagnosed With Long COVID (Post-Acute Sequelae of SARS CoV-2, PASC)
Suzi Hong¹, Marcos Monteon², Kathleen Bundy³, Chloe Delgado Ramirez³, Phoebe Senowitz³, Monica Guma⁴, Nina Acebo⁵, Chris Pruitt⁶, Tanya Shekhtman³, Shahrokh Golshan⁷ and Susan Lee⁸, ¹Herbert Wertheim School of Public Health and Human Longevity Science UCSD; Department of Psychiatry UCSD, San Diego, ²University of California, San Diego, San Diego, ³Department of Family Medicine, Center for Integrative Health, Krupp Endowment Fund, UCSD, La Jolla, ⁴University of California San Diego, San Diego, CA, ⁵University of California, San Diego, La Jolla, ⁶Herbert Wertheim School of Public Health and Human Longevity Science, UCSD, La Jolla, ⁷Department of Pyschiatry, UCSD, La Jolla, ⁸Department of Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: There have been over 777 million cases of acute COVID-19 infections worldwide as of April 2025. Although many patients recover, an estimated 10-30% of…
Abstract Number: 0060 • ACR Convergence 2025
Dietary Management of Rheumatoid Arthritis: A Functional Investigation of the Synbiotic Medical Food, SBD121
Ryan Green¹, Daniela Diaz-Infante Morales¹, Alicia Ballok¹, Kristine Kuhn², Christopher Ritchlin³, Mark Charbonneau¹, Eric Schott¹ and Gerardo Toledo¹, ¹Solarea Bio Inc, Waltham, MA, ²²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO, ³University of Rochester Medical Center, Canandaigua, NY
Background/Purpose: Rheumatoid arthritis (RA), affecting approximately 1% of the global population RA is a leading cause of disability worldwide. Despite available treatments, including methotrexate (MTX)…
Abstract Number: 2497 • ACR Convergence 2025
Unraveling the Complexity of Interferon Responses in Peripheral Blood Mononuclear Cells in Systemic Sclerosis at Single-Cell Resolution
Pietro Bearzi¹, Elena Pachera², Astrid Hofman³, Laura Much⁴, Lumeng Li¹, Kristina Bürki³, Cosimo Bruni⁵, Mike Becker⁶, Anna-Maria Hoffmann-Vold⁷, Roberto Giacomelli⁸ and Oliver Distler⁹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zürich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁵University of Zurich, Zurich, Switzerland, ⁶Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ⁷Oslo University Hospital, Oslo, Norway, ⁸i) Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Campus Biomedico; ii) Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome "Campus Bio-Medico", Rome, Italy, ⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Autoimmunity is a hallmark of SSc pathogenesis. Emerging evidence suggests that interferon (IFN) signaling plays a role in predicting SSc patients at risk of…
Abstract Number: 2070 • ACR Convergence 2025
Characterization of Hospitalization, Patient Demographics and Impact of Idiopathic Inflammatory Myopathies on Hospitalization Outcomes in Adult Fracture Patients: A National Inpatient Sample Analysis.
Pranathi Bandarupalli¹, Vineeth Potluri², Amr Alemairy², Harsharn Grewal² and Shudipan Chakraborthy², ¹Mercy St Vincent Medical Center, Toledo, OH, ²Mercy Health St. Vincent Medical Center, Toledo, OH
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM), including polymyositis and dermatomyositis, are rare systemic autoimmune disorders characterized by chronic muscle inflammation and progressive muscle weakness. Patients with…
Abstract Number: 1736 • ACR Convergence 2025
Multi-Model Evaluation of the Impact of CD14 on Synovial Inflammation and Pain During PTOA.
Kevin Burt¹, Sanique South², Natalie Adamczyk³, Shingo Ishihara³, Vu Nguyen⁴, Robert Mauck⁴, Anne-Marie Malfait⁵, Timothy Griffin⁶, Rachel Miller⁷ and Carla Scanzello¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Oregon, Eugene, ³Rush University, Chicago, ⁴University of Pennsylvania, Philadelphia, ⁵Rush University, Oak Park, IL, ⁶Oklahoma Medical Research Foundation, Oklahoma City, ⁷Rush University Medical Center, Chicago, IL
Background/Purpose: Soluble CD14, a co-receptor of inflammatory toll-like receptor signaling that is produced primarily by monocytes/macrophages, is present in synovial fluid in patients with OA…
Abstract Number: 1325 • ACR Convergence 2025
Plasma Matrix Metalloproteinases and Heart Failure Outcomes in Rheumatoid Arthritis
Tate Johnson¹, Michael Duryee¹, Punyasha Roul², Grant Cannon³, Gary Kunkel⁴, Beth Wallace⁵, Isaac Smith⁶, John Richards⁷, Katherine Wysham⁸, Gail Kerr⁹, Andreas Reimold¹⁰, Pascale Schwab¹¹, Daniel Anderson¹², Joshua Baker¹³, Geoffrey Thiele¹, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁵Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁶Duke University Hospital, Durham, NC, ⁷Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ⁸VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰Dallas VA Medical Center, Dallas, TX, ¹¹VA Portland and Oregon Health & Science University, Portland, OR, ^120587964, Durham, NC, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: The mechanisms of heart failure (HF) risk in RA remain incompletely understood. HF with preserved ejection fraction (HFpEF) is over-represented in RA, which may…
Abstract Number: 1114 • ACR Convergence 2025
Multi-omics Integration Analysis of the Cross-scale Mechanism of MTX-induced T2DM Risk and the Precise Intervention Strategy of Leonurine
Mei-Feng Shi¹, Fang-Shu Zou¹, Xiao-Na Ma¹, Wei Feng¹, Yi-Fang Zhang², Chang-Song Lin¹, Min-Ying Liu² and Qiang Xu¹, ¹Guangzhou University of Traditional Chinese Medicine, Guangzhou, China (People's Republic), ²The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China (People's Republic)
Background/Purpose: Methotrexate (MTX) is a first-line treatment for autoimmune diseases, including rheumatoid arthritis (RA). Its potential risk of inducing type 2 diabetes mellitus (T2DM) remains…
Abstract Number: 0654 • ACR Convergence 2025
Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial
Ed Vital¹, Benni Vargas², Julie Rae², Tracey Wang³, Jason Hackney², Cary Looney⁴, William Pendergraft², Liz Lightstone⁵, Brad Rovin⁶, Richard Furie⁷ and Harini Raghu², ¹University of Leeds, Leeds, England, United Kingdom, ²Genentech, Inc., South San Francisco, CA, ³Hoffmann-La Roche Ltd, Missssauga, ON, Canada, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁵Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁶The Ohio State University, Columbus, OH, ⁷Division of Rheumatology, Northwell Health, Great Neck, NY
Background/Purpose: Lupus nephritis (LN) is characterized by kidney inflammation. B cells play a central role in LN pathogenesis and type I interferon (IFN-I) pathway activation…
Abstract Number: 0463 • ACR Convergence 2025
Synovial fluid is a robust biomarker of synovial tissue inflammation in rheumatoid arthritis
Solana Cushing¹, Susan Goodman², Michael Parides¹, Hadeel Abdul-Rehman¹, Daniel Ramirez², Edward DiCarlo², Kristine Carandang³, Renee Davis⁴, Rebecca Blank⁵, Laura Donlin¹, Anna Helena Jonsson⁶, Amit Lakhanpal², Bella Mehta⁷, Dana Orange⁸ and Melanie smith², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, ⁴New York, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶University of Colorado School of Medicine, Aurora, CO, ⁷Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ, ⁸The Rockefeller University, New York, NY
Background/Purpose: Synovial tissue pathotype may indicate treatment response in RA, but synovial biopsies are not widely available. Synovial fluid (SF) is a promising surrogate. We…
Abstract Number: 0134 • ACR Convergence 2025
Neutrophil Gasdermin D Pores as Potential Therapeutic Targets in APS-Associated Thromboinflammation
NaveenKumar Somanathapura¹, Thalia Newman¹, Chao Liu², Srilakshmi Yalavarthi³, Cyrus Sarosh⁴, Jacqueline Madison¹, Ajay Tambralli¹, Yu (Ray) Zuo¹ and Jason S. Knight¹, ¹University of Michigan, Ann arbor, MI, ²University of Michigan, Superior Charter Twp, MI, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, ⁴University of Michigan, Temperance, MI
Background/Purpose: Emerging evidence implicates neutrophil activation and neutrophil extracellular trap (NET) formation (i.e., NETosis) in amplifying APS-associated thromboinflammation. Gasdermin D (GSDMD), a substrate of inflammatory…
Abstract Number: 0061 • ACR Convergence 2025
IL-22 Contributes to Autoantibody-induced Arthritis Via Modulation of Inflammatory Cytokine and Chemokine Expression in the Inflamed Synovium of a Murine Model
Shinjiro Kaieda¹, Suzuna Sugi¹, Takuma Koga², Takashi Kinoshita¹ and Tomoaki Hoshino¹, ¹Kurume university School of Medicine, Kurume, Japan, ²Kurume Universty School of Medicine, Kurume, Japan
Background/Purpose: IL-22 is a key cytokine involved in modulating tissue responses during inflammation and is markedly upregulated in inflammatory diseases, such as psoriasis, inflammatory bowel…
Abstract Number: 2495 • ACR Convergence 2025
IL-6/STAT3 Signaling is Central for Chemokine Production in E2-Induced Dermal Inflammation
Nicolas Ancona¹, Yucui Li², Ludivine Renaud³, Carol Feghali-Bostwick³ and DeAnna Baker Frost³, ¹MUSC Rheumatology & Immunology, Charleston, SC, ²Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi, Medical University Taiyuan, Shanxi, China (People's Republic), ³Medical University of South Carolina, Charleston, SC
Background/Purpose: Scleroderma (SSc) is an autoimmune disease characterized by dermal inflammation and fibrosis. Patients with SSc have high systemic levels of estradiol (E2), a form…
Abstract Number: 2046 • ACR Convergence 2025
Utilization of the All of Us Research Program to Study the Impact of Genetic Background on Autoinflammatory Diseases
Song Wu¹, Zuoming Deng², Peter Gorevic¹ and Qingping Yao¹, ¹Stony Brook University, Stony Brook, NY, ²Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: A widely recognized model of disease pathogenesis is the potential interplay of gene x gene x environment. Low penetrance variants in the NOD-like receptor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].